The follicular lymphoma therapeutics sector is expanding through diagnostic advancements and novel treatment development. Leading companies including Roche, Gilead, and Novartis are introducing innovative CD20-targeted therapies, bispecific antibo****s, and CAR-T treatments that enhance response durability and patient outcomes. Evolving clinical guidelines and biomarker integration are enabling more precise management approaches for this B-cell malignancy.
View Full Market Analysis: https://shorturl.at/l0iAr
Comment
Share
